Basilea expands ongoing Phase I/IIa clinical trial of BAL101553 to include glioblastoma patients

Swiss biopharmaceutical company Basilea has expanded its ongoing Phase I/IIa clinical trial of BAL101553 to include adult patients with recurrent or progressive glioblastoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news